ctDNA-guided choice of cetuximab versus bevacizumab with trifluridine/tipiracil for RAS/BRAF wild-type metastatic colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized phase 1/2 trial uses circulating tumor DNA (ctDNA) to confirm current RAS/BRAF wild-type status and guide a rechallenge strategy in patients with metastatic colorectal cancer who previously benefited from anti-EGFR therapy. Eligible patients are randomized to receive either cetuximab plus trifluridine/tipiracil or bevacizumab plus trifluridine/tipiracil, with routine ctDNA and radiographic monitoring. The design builds on prior phase II work suggesting EGFR rechallenge can work in molecularly selected patients and aims to compare efficacy and safety between the two combination regimens. Key outcomes include progression-free survival and response rates in ctDNA-confirmed RAS/BRAF wild-type patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed colorectal adenocarcinoma
* Initial RAS/BRAF wild-type status
* Received first-line treatment with FOLFOX, FOLFIRI, or FOLFOXIRI combined with cetuximab, with documented clinical benefit (CR/PR/SD) and progression-free survival (PFS) ≥ 6 months
* Disease progression occurred during or within 3 months after cetuximab-based first-line therapy
* Experienced further tumor progression after receiving second-line or subsequent treatments
* At least 4 months have elapsed since the last administration of cetuximab
* At least one measurable lesion according to RECIST v1.1
* RAS/BRAF wild-type status confirmed by blood-based ctDNA testing
* Normal hematologic function (platelets \> 90 × 10⁹/L; white blood cells \> 3 × 10⁹/L; neutrophils \> 1.5 × 10⁹/L; hemoglobin \> 10.0 g/100 ml)
* Serum bilirubin ≤ 1.5 × upper limit of normal (ULN), transaminases ≤ 5 × ULN
* No ascites, normal coagulation function, serum albumin ≥ 35 g/L
* Child-Pugh class A liver function
* Serum creatinine below ULN or calculated creatinine clearance \> 50 ml/min (using the Cockcroft-Gault formula)
* ECOG performance status of 0-1
* Expected survival \> 3 months
* Signed written informed consent
* Willing and able to undergo follow-up until death, study completion, or study termination

Exclusion Criteria:

* Presence of RAS or BRAF gene mutations
* Severe arterial embolism or ascites
* Bleeding tendency or coagulation disorders
* Hypertensive crisis or hypertensive encephalopathy
* Severe and uncontrolled systemic complications such as infections or diabetes
* Clinically significant cardiovascular diseases, including cerebrovascular accident (within 6 months prior to enrollment), myocardial infarction (within 6 months prior to enrollment), uncontrolled hypertension despite appropriate medical therapy, unstable angina, congestive heart failure (NYHA class II-IV), or arrhythmias requiring medical treatment History of or physical examination indicating central nervous system diseases (e.g., primary brain tumor, epilepsy not controlled with standard therapy, any brain metastases, or history of stroke)
* History of other malignancies within the past 5 years (excluding adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, and/or thyroid cancer)
* Known allergy to any of the study drugs
* Pregnant or breastfeeding women
* Women of childbearing potential (within 2 years of last menstruation) or men with reproductive potential who are not using or refuse to use effective non-hormonal contraception (e.g., intrauterine device, barrier method with spermicidal gel, or sterilization)
* Inability or unwillingness to comply with the study protocol
* Any other disease, functional impairment caused by metastatic lesions, or suspicious findings on physical examination that may indicate contraindications to study treatment or place the patient at high risk of treatment-related complications

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Deshen Wang, PhD
• Email: wangdsh@sysucc.org.cn
• Phone: 87342487

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Second-line treatment for advanced colorectal cancer using new chemotherapy options

  This study is testing a new combination of chemotherapy drugs to see if it can help people with advanced colorectal cancer who haven't had success with their first treatment.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06540326

• Petosemtamab plus chemotherapy vs standard chemo plus cetuximab or bevacizumab in RAS/BRAF WT colorectal cancer

  This phase 3 trial tests whether adding petosemtamab to standard chemotherapy works better than the usual chemo plus cetuximab or bevacizumab for people with recurrent, unresectable, or metastatic colorectal cancer that is KRAS/NRAS/BRAF wild type.

  Recruiting at 5 sites Phase 3 Genmab · Hot Springs, Arkansas and 4 other locations · NCT07775287

• Bevacizumab, sintilimab, cetuximab and irinotecan in refractory RAS wild-type metastatic colorectal cancer

  This trial tests whether adding sintilimab to a cetuximab and irinotecan backbone, with or without bevacizumab, helps patients with heavily pretreated metastatic colorectal cancer that has RAS wild-type tumors.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07722754

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

• Short-course radiotherapy plus intensified chemotherapy and targeted therapy with immunotherapy for high-risk rectal cancer

  This trial tests whether adding targeted therapy and a PD-1 inhibitor to a short course of radiotherapy and standard chemotherapy helps high-risk pMMR/MSS rectal cancer patients, compared with the same radiotherapy and chemotherapy alone.

  Recruiting Phase 3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07549399

• AMT-676 combinations for advanced colorectal cancer

  This study tests AMT-676 together with standard chemotherapy and targeted therapies to see if it’s safe and effective for people with unresectable advanced colorectal cancer.

  Recruiting at 8 sites Phase 2 Multitude Therapeutics Inc. · Fuzhou, Fujian and 18 other locations · NCT07474727

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.